Serological response to a third booster dose of BNT162b2 COVID‐19 vaccine among seronegative cancer patients

BACKGROUND AND AIM: The BNT162b2 COVID‐19 vaccine (Pfizer/BioNTech), given as a two‐dose series, 3 weeks apart, elicits a serological response in 84–98% of patients with cancer, even if administered while undergoing anticancer treatments. Herein, we report the impact of a third (booster) dose of BNT...

Descripción completa

Detalles Bibliográficos
Autores principales: Shmueli, Einat Shacham, Lawrence, Yaacov R., Rahav, Galia, Itay, Amit, Lustig, Yaniv, Halpern, Naama, Boursi, Ben, Margalit, Ofer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347981/
https://www.ncbi.nlm.nih.gov/pubmed/35652556
http://dx.doi.org/10.1002/cnr2.1645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347981/
https://www.ncbi.nlm.nih.gov/pubmed/35652556
http://dx.doi.org/10.1002/cnr2.1645

Ejemplares similares